Call for Abstracts

Abstracts & Awards > Call for Abstracts

Abstracts & Awards

Program & Abstracts

The Program Committee invites the submission of scientific abstracts for the IASLC 2025 World Conference on Lung Cancer (#WCLC25). The submission deadline is April 4, 2025 @ 23:59 PDT.

Please review the submission guidelines carefully as they have been updated for WCLC 2025.

January 31, 2025
Abstract Submission Opens

April 4, 2025 (23:59 PDT)
Abstract Submission Deadline

April 4, 2025 (23:59 PDT)
Education Awards Application Deadline

May 28, 2025
Notification of Abstract Acceptance

May 28, 2025
Notification of Education Awards

July 11, 2025 (23:59 PDT)
Presenting Author Registration Deadline

July 22, 2025 (10:00 PDT)
Abstract Title Release (not incl. LBA)

July 30, 2025 (23:59 PDT)
Late-Breaking Abstract (LBA) Submission Deadline

August 6, 2025
Late-Breaking Abstract Notifications

August 8, 2025 (10:00 PDT)
Late-Breaking Acceptance Deadline

August 13, 2025 (10:00 PDT)
Full Abstract Release Date
(Except for Embargoed Abstracts)

Abstract Submission Tracks

Risk Factors, Risk Reduction & Tobacco Control
  • Classic epidemiology
  • Gender differences
  • Lung cancer in persons who have never smoked
  • Exposure to radon, asbestos, and other environmental factors
  • Air pollution
  • Tobacco exposure or other aspects of tobacco including cessation programs
  • Chemoprevention
  • Efforts to reduce tobacco production, sales and distribution
  • Other topic in risk factors, risk reduction, and tobacco control
Tumor Biology – Preclinical Biology
  • In vitro basic science studies
  • Cell lines
  • Other topic in tumor biology – preclinical biology
Tumor Biology – Translational Biology
  • Patient derived cells
  • Animal models
  • Drug development studies
  • Other topic in tumor biology – translational biology
Screening and Early Detection
  • LDCT (Low-dose computed tomography)
  • Radiology
  • Methods to detect thoracic cancers
  • Technologies to detect thoracic cancers
Pulmonology and Staging
  • EUS (Endoscopic ultrasound)
  • EBUS (Endobronchial ultrasound)
  • NB (Navigational bronchoscopy)
  • (PET)-CT (Positron emission tomography)
  • Mediastinoscopy
  • Staging system analysis
Pathology and Biomarkers
  • Anatomic pathology
  • Molecular pathology
  • Tissue biomarker studies
  • Circulating biomarker studies
  • Clinical trial associated predictive biomarkers
Early-Stage Non-small Cell Lung Cancer

Clinical related studies on localized/early-stage NSCLC

  • Surgery
  • Radiation therapy
  • Neoadjuvant therapy
  • Adjuvant therapy
  • Immunotherapy
  • Targeted therapy
Local-Regional Non-small Cell Lung Cancer

Clinically related studies on local-regional/locally advanced NSCLC (Stage III)

  • Surgery
  • Radiation therapy
  • Neoadjuvant therapy
  • Adjuvant therapy
  • Immunotherapy
  • Targeted therapy
  • New multi-modality approaches
Metastatic Non-small Cell Lung Cancer – Local Therapies

Metastatic/advanced NSCLC related to

  • Radiation therapy
  • Surgery
  • Other ablative techniques
Metastatic Non-small Cell Lung Cancer – Antibody-Drug Conjugate and Cytotoxic Therapy

Clinically relevant studies in metastatic/advanced NSCLC –

  • Chemotherapy
  • Nonclassical chemotherapy agents (i.e. ADCs)
  • New drugs
  • New combinations
  • New sequencing of drugs
Metastatic Non-small Cell Lung Cancer – Immunotherapy

Clinically relevant studies in metastatic/advanced NSCLC related to –

  • Immunotherapy
  • New drugs
  • New combinations
  • New sequencing of drugs
Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Clinically relevant studies in metastatic/advanced NSCLC related to

  • Targeted therapy
  • New drugs
  • New combinations
  • New sequencing of drugs
Small Cell Lung Cancer and Neuroendocrine Tumors
  • Clinically related studies on small cell lung cancer
  • Clinically related studies on neuroendocrine tumors
Mesothelioma, Thymoma, and Other Thoracic Tumors
  • Clinically related studies on mesothelioma
  • Clinically related studies on thymoma
  • Clinically related studies on thymic carcinoma
  • Other thoracic tumors
Multidisciplinary Care: Nursing, Allied Health and Palliative Care
  • Allied health
  • Decision making
  • Decision support techniques
  • Ethics
  • Integrative care
  • Nursing
  • Palliative
  • Physiotherapy
  • Quality of live
  • Rehabilitation
  • Supportive care
  • Survivorship care in the context of nursing and allied health
  • Symptom management
  • Other topic in multidisciplinary care
Patient Advocacy
  • Patient survivorship from patient perspective
  • Community outreach
  • Patient-driven research
  • Advocacy
  • Patient reported outcomes
  • Lung cancer stigma
  • Other topic in patient advocacy
Global Health, Health Services, and Health Economics
  • Real-world database studies across tumor types and stages
  • Disparities identification
  • Disparities solutions
  • Studies that examine the cost-effectiveness of therapies
  • Diagnostics
  • Pathway implementation
  • Programs that help improve the efficiency of health system
  • Programs that help improve the efficiency of patient management
  • Registry creation descriptions
  • Other topic in global health, health services, and health economics

Abstract Types Accepted

Regular Abstract

Definition: Original scientific research that summarizes work done and major research findings.

Required sections for abstract submission:

  • Introduction
  • Methods
  • Results
  • Conclusion
Clinical Trials in Progress (eligible for designation as poster or e-poster only)

Definition: Ongoing trials that have not reached pre-specified endpoints for analysis.

Required sections:

  • Introduction
  • Methods

Optional sections:

  • Results
  • Conclusion
Case Report (eligible for designation as poster or e-poster only)

Definition: Detailed report of symptoms, signs, diagnosis, treatment and follow up of an individual patient. Must include a minimum of three (3), but preferably five (5) cases.

Required sections:

  • Introduction including selective literature review
  • Methods
  • Results
  • Conclusion
Late-Breaking Abstract (LBA) Submission

Definition:

  • LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines.
  • LBA designation is not a means for extending the regular abstract deadline. Highly impactful studies that have complete data should be submitted as a regular abstract and will be considered for a prominent oral presentation based on scoring by the program committee.
  • For abstracts that do not meet LBA requirements the authors will be given 5 business days to update the submitted data before the abstracts are re-classified as regular abstracts and rated based on the updated information.

Submission requirements:

Authors of LBA must submit an intent to submit an LBA abstract through the abstract portal by April 4, 2025 (23:59 PDT).

Required sections for intent to submit an LBA, which must be submitted by the April 4, 2025 deadline:

  • Explanation of why the abstract qualifies as late-breaking
  • Introduction
  • Methods, including applicable endpoints
  • Types of anticipated analysis and data to be reported

LBA Eligibility Review:

The Scientific Program Committee will review all submissions with the intent to submit LBA abstracts after the regular abstract submission deadline April 4, 2025. Authors of approved LBAs applications will be notified and advised on the processes for submitting final data by July 30, 2025. Authors of abstracts not being accepted for LBA submissions will be notified and given 5 days to submit all available data before the abstract is re-classified as a regular abstract and included in the regular abstract review and scheduling process.

LBA Simultaneous Publication to Journal of Thoracic Oncology:

The Journal of Thoracic Oncology offers simultaneous online publication for select high-impact abstracts in the late-breaking abstract category for WCLC 2025. If you have submitted an intent to submit a late-breaking abstract and believe your work is practice-changing, please send a pre-submission inquiry and cover letter detailing your work to [email protected], with “WCLC Simultaneous Publication” in the subject line no later than April 25, 2025.

Required sections for final LBA abstract, which must be submitted by July 30, 2025 (23:59 PDT):

  • Introduction
  • Methods, including applicable endpoints
  • Results
  • Conclusion

LBA abstracts not completed by the July 30 deadline will be automatically withdrawn and will not be considered for the Conference. Exceptions may be granted in exceptional circumstances. The Scientific Program Committee will review the final LBA data and notify the authors of its disposition by August 6, 2025. Authors must accept/decline the presentation within 48 hours of notification.

Abstract Submission Guidelines

Abstract Submission Guidelines

Word Limit: 500 words (does not include title and authors)

Abstracts should be organized into different sections based on the selected abstract type. Please refer to the ‘Abstract Type’ section on this page for further information. 

Title Word Limit: 125 characters total (including spaces)

Tables: No limit; each table counts as 100 words

Images: 2 maximum; each image counts as 100 words

Format(s): Upload tables, images and graphs in GIF, JPEG, JPG or PNG format of a minimum of 300 dpi and 100% size. Higher resolution is strongly preferred. 

Language: English 

AI Disclaimer: If you use AI technology when creating the content for your presentation or when writing you abstract, we require you to disclose to the learners or reviewers what AI tools were used as a footnote in the abstract.

IASLC Language Guide: To ensure high-quality oral and written presentations at IASLC Conferences, authors are required to create abstract titles based on the IASLC Language Guide. Titles that do not adhere to the Guide may be revised. We encourage you to review the Guide before submitting your abstract to minimize the need for revisions and to promote clear, respectful communication.

Studies: Indicate if the abstract is a phase 1, 2 or 3 study including the clinical trial identifier number.

  • Phase 1
  • Single Arm Phase 2
  • Randomized Phase 2
  • Phase 3

Fee: No submission fee 

Presenting Author Limit: Authors can only be listed as the Presenting Author on two (2) abstracts but can be co-author on any number of abstracts.

Number of Co-authors: There is a limit of 50 co-authors per abstract.

Plagiarism Policy

Definition: Plagiarism encompasses any of the following:

  1. Direct: intentionally submitting another person’s words or ideas verbatim as one’s own; 
  2. Self-plagiarism: submitting work that has been previously published or presented; 
  3. Mosaic plagiarism: stringing together portions of text from other sources; and 
  4. Lack of attribution: failing to appropriately identify and cite sources for language or ideas that are incorporated. 

For more information see: Das N, Panjabi M. Plagiarism: Why is it such a big issue for medical writers? Perspect Clin Res. 2011;2(2):67–71. doi:10.4103/2229-3485.80370  

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121267/   

  • Screening: IASLC screens all abstracts using anti-plagiarism software. Abstracts identified as having high levels of potentially plagiarized content will be evaluated by IASLC staff and appropriate actions taken. 
  • Penalties for plagiarism may include rejection of abstract and/or author(s) banned from making presentations at IASLC conferences. 
Independence of Educational Activities Policy
  • Employees of ACCME defined ineligible companies are prohibited from presenting educational content for Continuing Medical Education. Consequently, employees of ineligible companies are prohibited from giving presentations during accredited CME sessions (e.g., Presidential and plenary symposia, invited educational sessions). 
  • In situations where the presenting author is an employee of an ineligible company, the abstract will automatically be considered for a poster or e-poster. 
  • Presenting authors must be registered for WCLC 2025 independent of an ineligible company, except for employees of ineligible companies, who are allowed to be registered by their employers. 
  • The presenting author must control all content. Ineligible companies may not influence scientific content by requiring the use of company slide decks or other materials. Scientific data generated by industry sponsored research is permissible. 
  • Content of educational activities must be well-balanced, evidence based and unbiased. Generic names should be used to the extent possible. 
  • Ineligible companies/commercial interests may not submit registration materials or fees on behalf of learners, faculty or others attendee types. 
Encore Submissions

An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract.

Publication

Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the Conference proceedings. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation. 

Associated manuscripts for any abstract selected for presentation at WCLC can be submitted to a peer reviewed journal but must not be published prior to the presentation at WCLC. Simultaneous publications are encouraged.

Embargo and Confidentiality

Confidentiality

Upon submission to the WCLC, all abstracts and study data intended for presentation at the Conference are held in confidence. This confidentiality policy applies to previously presented abstracts at WCLC only with regard to new or updated data or information within the study.

Before the abstract information is made public in conjunction with the WCLC Conference, the following parties – the author, co-authors, research sponsor, journalists, and others – are prohibited from:

  • Disclosing the information to the public or sharing it with entities that may make it public, such as news media
  • Using the information for securities trading purposes or providing it to others for such purposes

Confidentiality restrictions are lifted when WCLC publishes the abstracts online in conjunction with the Conference. Once IASLC makes the abstract publicly available, the Confidentiality Policy becomes inactive, allowing authors to openly discuss their study findings. However, formal presentations, including slides, posters, and recordings of the study data, remain exclusive to WCLC.

In cases where an abstract or its data is released in a manner that violates WCLC’s Confidentiality Policy after submission, the abstract may become ineligible for inclusion in the WCLC Conference. Exceptional circumstances may be considered if an official Confidentiality Policy Exception is applicable.

Embargo

All abstracts accepted for presentation – with the exception of abstracts included in the WCLC press program – will have their titles released on July 22, 2025 at 10:00 PDT and the full text released on August 13, 2025 at 10:00 PDT.

Abstracts selected for inclusion in the WCLC press program, including Presidential Symposia abstracts, will be kept under embargo until either the time of the presentation or the beginning of the WCLC press conference in which it is presented, whichever comes first.

Journal of Thoracic Oncology

The Journal of Thoracic Oncology offers simultaneous online publication for select high-impact abstracts in the late-breaking abstract category for WCLC 2025. If you have submitted an intent to submit a late-breaking abstract and believe your work is practice-changing, please send a pre-submission inquiry and cover letter detailing your work to [email protected], with “WCLC Simultaneous Publication” in the subject line no later than April 25, 2025.

Frequently Asked Questions

When will the abstract titles be published online?

Abstract titles will be released July 22, 2025 (10:00 PDT). 

When will the full abstracts be published online?

The full abstract bodies will be released on August 13, 2025 at 10:00 PDT, except those abstracts included in the WCLC 2025 Press Program. 

Abstracts selected for inclusion in the WCLC press program, including Presidential Symposium abstracts, will be kept under embargo until either the time of the presentation or the beginning of the WCLC press conference in which it is presented, whichever comes first.

Does WCLC accept abstracts that have been submitted and presented to a previous Conference (ie, encore abstracts, trials in progress encore abstracts)?

An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the presentation. Submitters are required to list any previous presentations during the abstract submission process.

Are case reports/case series considered for presentations?

The submission of single case reports is not permitted, however, submission of case series with a minimum of 3 cases but preferably 5, including literature review is accepted.

What is the withdraw deadline for regular submissions and late breaking submissions?

July 11, 2025 is the withdrawal deadline for regular abstracts and August 9, 2025 for LBA abstracts.

The presenting author registration deadline (except LBA abstracts) is July 11, 2025 (23:59 PDT). Abstract presentations for a presenter (except LBA abstracts) not registered by this date will be withdrawn from the program. 

For late-breaking abstracts, does the Conference only permit abstracts that report on Phase 3 [and higher] studies?
  • LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines. Examples include randomized phase II and/or III trials, and large single arm phase II trials in rare subtypes of thoracic malignancies. LBA’s in other disciplines that change clinical practice within the year will also be considered.
  • LBA designation is not a means for extending the regular abstract deadline. Highly impactful studies that have complete data should be submitted as a regular abstract and will be considered for a prominent oral presentation based on scoring by the program committee.
  • For abstracts that do not meet LBA requirements the authors will be given 5 business days to update the submitted data before the abstracts are re-classified as regular abstracts and rated based on the updated information.
Could I send my manuscript to publish to a journal in my country before WCLC?

Associated manuscripts for any abstract selected for presentation at WCLC can be submitted to a peer reviewed journal but must not be published prior to the presentation at WCLC. Simultaneous publications are encouraged.

Is industry allowed to be in lead or senior author positions on the author list for WCLC abstract submissions? Are there restrictions towards pharmaceutical/commercial authors on presenting abstracts at the meeting?

Yes, industry is permitted to be in the lead and senior author positions in the author list of an abstract. However, Industry/pharmaceutical/commercial authors are prohibited from presenting Presidential, Oral, and Mini Oral presentations. Industry/pharmaceutical/commercial authors are permitted to present poster or e-poster presentations. 

Would it be possible to submit an abstract without results and conclusion?

All Regular Abstracts, Clinical Trials in Progress Abstracts, and Case Series abstracts must be fully completed by the April 4, 2025 deadline.

Any Regular Abstracts and Case Series that are incomplete after the April 4, 2025 deadline will be automatically withdrawn and will not be considered for the meeting. Clinical Trials in Progress abstracts may be submitted and completed by the April 4, 2025 deadline without Results and Conclusions as those sections are optional for CTPS submissions.

To submit a late-breaking abstract, you must submit an intent to submit an abstract including all components of the abstract except for the Results and Conclusions by the April 4, 2025 deadline.

Is there a limit on the number of abstracts in which an author can be lead author?

Authors can only be listed as the Presenting Author on two (2) abstracts but can be co-author on any number of abstracts.

Is there any charge for the submission of abstracts, and if so, how much is it?

There is no charge to submit an abstract to WCLC. 

The authors of the abstract, however, IASLC reserves the right to sell and retain any revenue/income from selling the abstracts, presentation materials or recordings of the presentations. Please refer to the detailed terms and conditions that authors have to agree to during the abstract submission.

Copyright is with the authors, however, IASLC reserves the right to publish and sell copies/recordings of the presentation materials.

Do clinical trials need to be registered at clinicaltrials.gov?

The clinical trials must be registered in clinicaltrials.gov or an applicable one from the country/regulatory body.

Does the recruitment of patients need to have been started by the abstract submission deadline for Clinical Trials in Progress?

No, it’s not required.

Is the presenting author required to be an IASLC member?

No.

Does the abstract submission need to be sponsored by an IASLC member?

No.

May systematic review abstracts be submitted to the WCLC?

Systematic review abstracts are not considered original research and should not be submitted to the WCLC.

Contact

For inquiries, please contact  [email protected]. If your inquiry is regarding a particular draft or submission, please include the abstract ID in your email. 

Scroll to Top